AAV-U7snRNA mediated multi exon-skipping for Duchenne muscular dystrophy

AAV-U7snRNA mediated multi exon-skipping for Duchenne muscular dystrophy

Show other versions (1)

Bibliographic Details
Main Authors:	Goyenvalle, A, Babbs, A, Garcia, L, Davies, K
Format:	Conference item
Published:	2010

Similar Items

AAV-U7snRNA mediated multi exon-skipping for Duchenne muscular dystrophy
by: Goyenvalle, A, et al.
Published: (2011)

Engineering exon-skipping vectors expressing U7 snRNA constructs for Duchenne muscular dystrophy gene therapy.
by: Goyenvalle, A, et al.
Published: (2011)

Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy
by: Goyenvalle, A, et al.
Published: (2012)

Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy.
by: Goyenvalle, A, et al.
Published: (2012)

Upgrading U7snRNA To Complete Efficient Rescue of Dystrophin by Exon-Skipping in DMD Patients
by: Goyenvalle, A, et al.
Published: (2009)

Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping
by: Goyenvalle, A, et al.
Published: (2012)

Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping.
by: Goyenvalle, A, et al.
Published: (2012)

AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy
by: Le Hir, M, et al.
Published: (2013)

Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy.
by: Goyenvalle, A, et al.
Published: (2009)

The Cellular Processing Capacity Limits the Amounts of Chimeric U7 snRNA Available for Antisense Delivery.
by: Eckenfelder, A, et al.
Published: (2012)

New Approach for Antisense Oligonucleotide-Mediated Exon Skipping in Duchenne Muscular Dystrophy.
by: Aoki, Y, et al.
Published: (2012)

Targeting Duchenne muscular dystrophy by skipping DMD exon 45 with base editors
by: Michael Gapinske, et al.
Published: (2023-09-01)

Assessment of the feasibility of exon 45–55 multiexon skipping for duchenne muscular dystrophy
by: van Ommen Gert-Jan B, et al.
Published: (2008-12-01)

Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis
by: Yuko Shimizu-Motohashi, et al.
Published: (2018-06-01)

Rescue of cardiomyopathy through U7snRNA‐mediated exon skipping in Mybpc3‐targeted knock‐in mice
by: Christina Gedicke‐Hornung, et al.
Published: (2013-05-01)

Possibility of exon skipping therapy for Duchenne muscular dystrophy in Russian patients: present and future
by: E. V. Zinina, et al.
Published: (2024-09-01)

The Cellular Processing Capacity Limits the Amounts of Chimeric U7 snRNA Available for Antisense Delivery
by: Agathe Eckenfelder, et al.
Published: (2012-01-01)

Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse
by: Nicolas Wein, et al.
Published: (2022-09-01)

Exon skipping peptide-pmos for correction of dystrophin in mouse models of duchenne muscular dystrophy
by: Betts, C, et al.
Published: (2014)

Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy.
by: Goyenvalle, A, et al.
Published: (2011)

Challenges for antisense oligonucleotide-based therapeutics, in particular for exon 51-skipping in Duchenne muscular dystrophy
by: Aoki, Y, et al.
Published: (2011)

CRISPR-Cas9-mediated exon skipping as a cardioprotective strategy in Duchenne muscular dystrophy
by: Harry Wilton-Clark, et al.
Published: (2023-09-01)

In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.
by: Wang, Q, et al.
Published: (2010)

Rescue of common and rare exon 2 skipping variants of the GAA gene using modified U1 snRNA
by: Paolo Peruzzo, et al.
Published: (2025-02-01)

Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy
by: Goyenvalle Aurélie, et al.
Published: (2011-02-01)

Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy.
by: Limin Cao, et al.
Published: (2014-01-01)

Novel Cationic Carotenoid Lipids as Delivery Vectors of Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy
by: Vassilia Partali, et al.
Published: (2012-01-01)

Persistence of exon 2 skipping and dystrophin expression at 18 months after U7snRNA-mediated therapy in the Dup2 mouse model
by: Liubov V. Gushchina, et al.
Published: (2023-12-01)

NS-065/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy
by: Naoki Watanabe, et al.
Published: (2018-12-01)

In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy.
by: Yusuke Echigoya, et al.
Published: (2015-01-01)

From diagnosis to therapy in Duchenne muscular dystrophy
by: Babbs, A, et al.
Published: (2020)

Digital Droplet PCR for the Absolute Quantification of Exon Skipping Induced by Antisense Oligonucleotides in (Pre-)Clinical Development for Duchenne Muscular Dystrophy.
by: Ruurd C Verheul, et al.
Published: (2016-01-01)

Cell-mediated exon skipping normalizes dystrophin expression and muscle function in a new mouse model of Duchenne Muscular Dystrophy
by: Francesco Galli, et al.
Published: (2024-03-01)

U1 snRNA interactions with deep intronic sequences regulate splicing of multiple exons of spinal muscular atrophy genes
by: Eric W. Ottesen, et al.
Published: (2024-07-01)

The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy
by: Guiraud, S, et al.
Published: (2019)

A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures.
by: Monika Hiller, et al.
Published: (2018-01-01)

Rescu of severely affected dystrophin/utrophin deficient mice by morpholino-oligomer mediated exon skipping
by: Goyenvalle, A, et al.
Published: (2010)

Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53.
by: Claudia Brogna, et al.
Published: (2019-01-01)

Progress in therapy for Duchenne muscular dystrophy.
by: Fairclough, R, et al.
Published: (2011)

Progress in therapy for Duchenne muscular dystrophy
by: Fairclough, R, et al.
Published: (2011)